Pages that link to "Q40384995"
Jump to navigation
Jump to search
The following pages link to Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family (Q40384995):
Displaying 50 items.
- Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review (Q26774874) (← links)
- Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets (Q26830569) (← links)
- Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma (Q27027729) (← links)
- Tocilizumab: a review of its use in the management of rheumatoid arthritis (Q28241360) (← links)
- Methotrexate Is a JAK/STAT Pathway Inhibitor (Q28546079) (← links)
- The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials (Q30914777) (← links)
- Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials (Q31151183) (← links)
- Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor (Q33400381) (← links)
- Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. (Q33802181) (← links)
- Structural pathways of cytokines may illuminate their roles in regulation of cancer development and immunotherapy. (Q33820227) (← links)
- Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy (Q33851168) (← links)
- Impact of interleukin-6 in hematological malignancies (Q34387624) (← links)
- Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of t (Q34394122) (← links)
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial (Q34795777) (← links)
- Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer (Q35058009) (← links)
- Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry (Q35258244) (← links)
- Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). (Q35350912) (← links)
- The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis (Q35429154) (← links)
- Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial (Q35605487) (← links)
- Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East (Q35674568) (← links)
- Immunological response as a source to variability in drug metabolism and transport (Q35749503) (← links)
- The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis (Q35864053) (← links)
- STAT1 is Constitutively Activated in the T/C28a2 Immortalized Juvenile Human Chondrocyte Line and Stimulated by IL-6 Plus Soluble IL-6R (Q35882038) (← links)
- Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab (Q35982627) (← links)
- Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy (Q36113215) (← links)
- Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex (Q36283919) (← links)
- Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica (Q36295700) (← links)
- Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis (Q36396550) (← links)
- Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab (Q36919914) (← links)
- Stat5 as a diagnostic marker for leukemia (Q37035281) (← links)
- Tocilizumab: the first interleukin-6-receptor inhibitor (Q37226317) (← links)
- Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis (Q37358242) (← links)
- Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials (Q37465459) (← links)
- Targeting IL-6 in the treatment of inflammatory and autoimmune diseases (Q37588720) (← links)
- The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. (Q37600827) (← links)
- Tocilizumab in the treatment of rheumatoid arthritis and beyond (Q37682799) (← links)
- Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis (Q37689966) (← links)
- Therapeutic opportunities in fibroblasts in inflammatory arthritis (Q37781917) (← links)
- Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis (Q37828398) (← links)
- IL-6/IL-6 receptor system and its role in physiological and pathological conditions (Q37949664) (← links)
- Assessing the safety of biologic agents in patients with rheumatoid arthritis (Q38020463) (← links)
- Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. (Q38021339) (← links)
- The role of tocilizumab in the management of rheumatoid arthritis (Q38030974) (← links)
- Targeting interleukin-6 in rheumatoid arthritis (Q38086137) (← links)
- Biological therapies for rheumatoid arthritis: progress to date (Q38096206) (← links)
- Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis (Q38155126) (← links)
- Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis (Q38164315) (← links)
- Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment (Q38176004) (← links)
- Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure (Q38183314) (← links)
- B cells in MS and NMO: pathogenesis and therapy (Q38212081) (← links)